Phosphorus acid, alkyl substituted [1,1'-biphenyl]-2,2'-diyl-tetra-aryl ester

Endpoint summary

Description of key information

At Annex VII, only an acute oral test was conducted as this was considered the most likely route of exposure.

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records

Reference

Endpoint:

acute toxicity: oral

Type of information:

experimental study

Adequacy of study:

key study

Study period:

From 2013-9-25 to 2014-01-15

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Report of study in accordance with OECD guideline and GLP

Qualifier:

according to guideline

Guideline:

OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)

Deviations:

no

GLP compliance:

yes

Test type:

acute toxic class method

Limit test:

yes

Species:

rat

Strain:

Wistar

Sex:

female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: Charles River Deutschland, Sulzfeld, Germany
- Age at study initiation: Approx. 8-9 weeks old
- Weight at study initiation: 159 to 172 (mean=165)g
- Fasting period before study: overnight prior to dosing
- Housing: Group housing of 3 animals per cage
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: at least 5 days

ENVIRONMENTAL CONDITIONS
- Temperature (°C):18 to 24 °C
- Humidity (%): 40 to 70%
- Air changes (per hr): 15 times
- Photoperiod (hrs dark / hrs light): 12-hour light /12-hour dark

IN-LIFE DATES: From: 2013-10-10 To: 2013-10-30

Route of administration:

oral: gavage

Vehicle:

propylene glycol

Details on oral exposure:

Oral gavage, using plastic feeding tubes.
Vehicle: Propylene glycol (Merck, Darmstadt, Germany) (specific gravity 1.036)
Preparation: The formulations (w/w) were prepared within 4 hours prior to dosing. Homogeneity was accomplished to a visually acceptable level. Adjustment was made for specific gravity of the vehicle. No correction was made for purity of the test substance.

Doses:

2000mg/kg (10mg/kg) body weight

No. of animals per sex per dose:

3

Control animals:

yes

Details on study design:

Observations
-Mortality/Viability: Twice daily.
-Body weights Days 1 (pre-administration), 8 and 15.
-Clinical signs At periodic intervals on the day of dosing (Day 1) and once daily thereafter, until Day 15.
The symptoms were graded according to fixed scales and the time of onset, degree and duration were recorded.
-Necropsy: At the end of the observation period, all animals were sacrificed by oxygen/carbon dioxide procedure and subjected to necropsy.
Descriptions of all internal macroscopic abnormalities were recorded.

Sex:

female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Mortality:

No mortality occurred.

Clinical signs:

other: Hunched posture and piloerection were noted for most animals between Days 1 and 4.

Gross pathology:

No abnormalities were found at macroscopic post mortem examination of the animals.

Interpretation of results:

practically nontoxic

Remarks:

Migrated information Criteria used for interpretation of results: OECD GHS

Conclusions:

The oral LD50 value of the test substance in Wistar rats was established to exceed 2000 mg/kg body weight.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Additional information

The oral LD50 value of the test substance in Wistar rats was established to exceed 2000 mg/kg body weight.

Justification for selection of acute toxicity – oral endpoint
Only study available